It might now be possible to predict which lung cancer patients will benefit most from immunotherapy treatment.
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment, according to a Cancer Research UK funded study published today (Monday) in Nature Immunology.
Researchers at the University of Southampton and La Jolla Institute for Allergy & Immunology, California, found that lung cancer patients* with large amounts of a particular type of immune T-cell, called tissue-resident memory T-cells, in their tumour were 34 per cent less likely to die.
The study also found that it was not just the numbers of cells that increased survival, but the cells’ behaviour played a key role. The cells clustered together and ‘took up residency’ in a particular tissue, in this case the cancer tissue, to protect the patient.
These new T-cells also produce other molecules that attack the tumour, meaning that the body’s immune system could be more likely to hunt out and destroy cancer cells.
Immunotherapies have shown great promise in the last decade, but identifying which patients respond to treatment and which don’t has proven difficult.
In future, testing for levels of these cells could help doctors identify which patients will benefit most from immunotherapies that help to ramp up the body’s attack on the cancer.
Read full article: Discovery could guide immunotherapy for lung cancer | Cancer Research UK
|Read Full Article: Discovery could guide immunotherapy for lung cancer | Cancer Research UK|